Zobrazeno 1 - 10 of 91 pro vyhledávání: '"David, Sherris"'
3
Akademický článek
Characterization of Small Molecules Inhibiting the Pro-Angiogenic Activity of the Zinc Finger Transcription Factor Vezf1
Autor: Ming He, Qianyi Yang, Allison B. Norvil, David Sherris, Humaira Gowher
Publikováno v: Molecules, Vol 23, Iss 7, p 1615 (2018)
Discovery of inhibitors for endothelial-related transcription factors can contribute to the development of anti-angiogenic therapies that treat various diseases, including cancer. The role of transcription factor Vezf1 in vascular development and reg
Externí odkaz: https://doaj.org/article/3bd977948705422e947f1622f9dc918e
Zobrazit plný text záznamu
4
Akademický článek
Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy
Autor: Jorge L. Jacot, David Sherris
Publikováno v: Journal of Ophthalmology, Vol 2011 (2011)
Novel therapeutics such as inhibitors of PI3K/Akt/mTOR pathway presents a unique opportunity for the management of diabetic retinopathy (DR). Second generation mTOR inhibitors have the prospect to be efficacious in managing various stages of disease
Externí odkaz: https://doaj.org/article/54d0c2d2cdfc407182314220526d7675
Zobrazit plný text záznamu
5
The Novel mTOR Complex 1/2 Inhibitor P529 Inhibits Human Lung Myofibroblast Differentiation
Autor: Nathan Sandbo, Keith T. Ferguson, Ksenija Bernau, David Sherris, Elizabeth E. Torr, Jonathan P Leet
Publikováno v: Journal of Cellular Biochemistry. 118:2241-2249
Idiopathic pulmonary fibrosis is a progressive and deadly disorder with very few therapeutic options. Palomid 529 (8-(1-hydroxyethyl)-2-methoxy-3-(4-methoxybenzyloxy)-benzo[c]chromen-6-one; P529) is a novel dual inhibitor of mechanistic target of rap
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4179680b89c1cce4a4b65bfcd818f397
https://doi.org/10.1002/jcb.25878
Zobrazit plný text záznamu
6
The brain penetrating and dual TORC1/TORC2 inhibitor, RES529, elicits anti-glioma activity and enhances the therapeutic effects of anti-angiogenetic compounds in preclinical murine models
Autor: Francesco Marampon, Andrea Mancini, Flora Vitale, Giovanni Luca Gravina, Stefano Martellucci, Vincenzo Mattei, Simona Pompili, Claudio Festuccia, Leda Biordi, Simona Delle Monache, David Sherris, Roberta Sferra, Alessandro Colapietro
Publikováno v: Cancers, Vol 11, Iss 10, p 1604 (2019)
Cancers
Volume 11
Issue 10
Background. Glioblastoma multiforme (GBM) is a devastating disease showing a very poor prognosis. New therapeutic approaches are needed to improve survival and quality of life. GBM is a highly vascularized tumor and as such, chemotherapy and anti-ang
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee621de376289bf9c588e851612fe48d
http://hdl.handle.net/11573/1361371
Zobrazit plný text záznamu
7
Characterization of Small Molecules Inhibiting the Pro-Angiogenic Activity of the Zinc Finger Transcription Factor Vezf1
Autor: David Sherris, Ming He, Allison B. Norvil, Qianyi Yang, Humaira Gowher
Publikováno v: Molecules, Vol 23, Iss 7, p 1615 (2018)
Molecules
Volume 23
Issue 7
Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry
Discovery of inhibitors for endothelial-related transcription factors can contribute to the development of anti-angiogenic therapies that treat various diseases, including cancer. The role of transcription factor Vezf1 in vascular development and reg
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b80e613383cf8abade7e5566987cbaf8
http://www.mdpi.com/1420-3049/23/7/1615
Zobrazit plný text záznamu
8
Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models
Autor: F. Vittorini, Emmanuele A. Jannini, Giovanni Luca Gravina, David Sherris, Vincenzo Tombolini, Andrea Lenzi, Claudio Festuccia, Ernesto Di Cesare, Francesco Marampon
Publikováno v: The Prostate. 74:852-868
BACKGROUND P529, a Torc1/Torc2 inhibitor, has demonstrated its potential as a radiosensitizer. However the molecular mechanisms underlying this phenomenon still need to be elucidated. Aim of this study is to dissect molecular mechanisms regulating th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ac287ee9a2f6fbf53b69ea30d455822f
https://doi.org/10.1002/pros.22804
Zobrazit plný text záznamu
9
Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood-Brain Barrier without restriction by ABCB1 and ABCG2
Autor: Levi C.M. Buil, Fan Lin, Olaf van Tellingen, David Sherris, Jos H. Beijnen
Publikováno v: International Journal of Cancer. 133:1222-1233
Palomid 529, a novel dual mTORC1/2 inhibitor has displayed interesting activities in experimental models and is a candidate for clinical evaluation. We have assessed the interaction of Palomid 529 with ATP-binding cassette (ABC) drug efflux transport
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4de0593aa099822949ba8ed106b12b83
https://doi.org/10.1002/ijc.28126
Zobrazit plný text záznamu
10
High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates
Autor: Olaf van Tellingen, Fan Lin, David Sherris, Jos H. Beijnen
Publikováno v: Journal of Chromatography B. 879:3823-3831
Palomid 529 (8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[ c ]chromen-6-one), is a novel non-steroidal small-molecule drug, which inhibits both mTORC1 and mTORC2 assembly, and elicits both anti-angiogenic and direct anti-tumor effects
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6053bab373a756434ba8185afcd0c46d
https://doi.org/10.1016/j.jchromb.2011.10.028
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje